<SEC-DOCUMENT>0001157523-11-003400.txt : 20110526
<SEC-HEADER>0001157523-11-003400.hdr.sgml : 20110526
<ACCEPTANCE-DATETIME>20110526105717
ACCESSION NUMBER:		0001157523-11-003400
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110526
FILED AS OF DATE:		20110526
DATE AS OF CHANGE:		20110526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICON PLC  /ADR/
		CENTRAL INDEX KEY:			0001060955
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-08704
		FILM NUMBER:		11872925

	BUSINESS ADDRESS:	
		STREET 1:		BANK OF NEW YORK
		STREET 2:		48 WALL ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10286
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6739167.htm
<DESCRIPTION>ICON??PLC 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font><br><br><br><font style="font-size: 12pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><br><font style="font-size: 12pt">Washington,
      D.C. 20549</font><br><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Report
      of Foreign Private Issuer</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Rule 13a-16 under</b></font><br>t<font style="font-size: 12pt; font-family: Times New Roman"><b>he
      Securities Exchange Act of 1934</b></font><br><br><br>For the month ended<font style="font-size: 10pt; font-family: Times New Roman">
      May, 2011</font><br><br><br><font style="font-size: 18pt; font-family: Times New Roman"><b>ICON&#160;plc</b></font><br>(R<font style="font-size: 10pt; font-family: Times New Roman">egistrant's
      name)</font><br><br><br>0-29714<br>(Commission file number)<br><br><br>South
      County Business Park, Leopardstown, Dublin 18, Ireland<br>(Address of
      principal executive offices)<br><br>Ciaran Murray, CFO<br>South County
      Business Park Leopardstown, Dublin 18, Ireland.<br>Ciaran.Murray@iconplc.com<br>0011-353-1-291-2000<br>(Name,
      telephone number, email and/or facsmile number and address of Company
      contact person)<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant files or will file annual
      reports under cover Form 20-F or Form 40-F.<br>
    </p>
    <p style="text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<u><b>X</b></u>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<b>_</b>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(1):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(7):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant by furnishing the
      information contained in this Form is also thereby furnishing the
      information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<b>_</b>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p style="white-space: nowrap">
      If &quot;Yes&quot; is marked, indicate below the file number assigned to the
      registrant in connection with Rule 12g3-2(b):82&#160;&#160;&#160;&#160;&#160;&#160;<b>N/A</b><br><br>
    </p>
    <div style="width: 100%; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <u><font style="font-size: 10pt"><b>EXHIBIT&#160;LIST</b></font></u><br>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Exhibit</u>
          </p>
        </td>
        <td style="width: 2%">
          &#160;
        </td>
        <td style="width: 20%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Description</u>
          </p>
        </td>
        <td style="width: 72%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 20%">

        </td>
        <td style="width: 72%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="white-space: nowrap; width: 6%; text-align: left; padding-left: 0.0px; padding-right: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            99.1
          </p>
        </td>
        <td style="width: 2%">

        </td>
        <td colspan="2" style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Icon plc Press Release
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="width: 100%; margin-right: 0pt; margin-left: 0pt; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>ICON plc</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%; text-align: left; padding-left: 0.0px" valign="top">
          Date:
        </td>
        <td style="width: 55%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            May 26, 2011
          </p>
        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>/s/ Ciaran Murray</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Ciaran Murray
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6739167ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p>

    </p>
    <p style="text-align: center">
      <b>ICON Selected by Pfizer as a Global Strategic Partner for Clinical
      Research and Development</b>
    </p>
    <p style="text-align: center">
      <i><b>ICON Selected For Strength of Services, Quality and Regulatory
      Compliance and Collaboration Expertise</b></i>
    </p>
    <p>
      <b>Dublin, Ireland, May 26, 2011 &#8211; ICON plc, (NASDAQ: ICLR; ISIN:
      IE0005711209), </b>a global provider of outsourced development services
      to the pharmaceutical, biotechnology and medical device industries,
      today announced a strategic partnership with Pfizer Inc. (NYSE:PFE)
      which will see it serve as one of two preferred providers of clinical
      trial implementation services.
    </p>
    <p>
      The new partnership is part of Pfizer&#8217;s comprehensive program of change
      in R&amp;D to sharpen research focus, deliver differentiated innovation, and
      create a more flexible cost base through external partnerships for
      certain R&amp;D services. To be fully implemented over an 18 to 24 month
      period, the partnership will enable Pfizer to focus internally on its
      core capability in clinical trial design, while leveraging the strengths
      and scale of ICON to implement clinical development programs with
      greater efficiency and rigor.
    </p>
    <p>
      Under the partnership agreement, Pfizer will retain scientific ownership
      of the clinical development process, and maintain strict oversight and
      quality standards relating to patient safety and regulatory compliance.
      Pfizer will leverage ICON&#8217;s expertise in the areas of program initiation
      and management; site and country feasibility; data management and
      reporting set-up; program study drug logistics; scientific and medical
      communications; and quality assurance.
    </p>
    <p>
      Peter Gray, CEO at ICON plc, commented, &#8220;Today&#8217;s announcement is another
      significant indicator of ICON&#8217;s ability to partner with major companies
      in helping them transform their drug development model and validates the
      investments that we are making to capitalise on the changing market
      environment. We look forward to working with Pfizer to help realise
      their development pipeline and expect that over time our partnership
      will have a significant positive impact on ICON&#8217;s future growth.&#8221;
    </p>
    <p>
      <b>About ICON plc</b>
    </p>
    <p>
      ICON plc is a global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries. The Company
      specialises in the strategic development, management and analysis of
      programs that support clinical development - from compound selection to
      Phase I-IV clinical studies. ICON currently has approximately 7,700
      employees, operating from 77 locations in 39 countries.
    </p>
    <div style="width: 100%; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Further information is available at <u>www.iconplc.com</u>
    </p>
    <p>
      <i><b>DISCLOSURE NOTICE</b>: The information contained in this release
      is as of May 26, 2011. ICON assumes no obligation to update
      forward-looking statements contained in this release as a result of new
      information or future events or developments.</i>
    </p>
    <p>
      <i>This release contains forward-looking information about ICON&#8217;s
      strategic partnership with Pfizer, including the potential benefits of
      the partnership on ICON&#8217;s future financial results and condition that
      involves substantial risks and uncertainties. These risks and
      uncertainties include, among other things, the risk that the partnership
      results in more limited provision of services by ICON than expected,
      that those services do not have the expected financial impact on ICON or
      that the partnership is terminated.</i>
    </p>
    <p>
      <i>A further description of risks and uncertainties can be found in
      ICON&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31,
      2010 and in its Reports of Foreign Issuer on Form 6-K filed with the US
      Securities and Exchange Commission.</i>
    </p>
    <p>
      ICON/ICLR-F
    </p>
    <p>
      <b>Contacts</b><br>Sam Farthing<br>VP Investor Relations<br>ICON plc<br>+
      353-1-291-2000
    </p>
    <p>
      Rosie Allan<br>Weber Shandwick<br>+44 (0)20 7067 0190
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
